Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -178.91M | -95.84M | -97.54M | -91.37M | -93.00M |
| Total Depreciation and Amortization | 12.95M | 7.20M | 8.97M | 7.38M | 7.55M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.48M | 26.75M | 16.62M | 18.15M | 22.64M |
| Change in Net Operating Assets | 6.05M | 2.67M | -10.26M | -36.45M | -11.27M |
| Cash from Operations | -115.43M | -59.23M | -82.22M | -102.30M | -74.08M |
| Capital Expenditure | -1.30M | -4.56M | -1.18M | -6.65M | -2.07M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 277.10M | -- | -- | -- | -71.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -350.00K | 0.00 | -3.00M | -- | -350.00K |
| Cash from Investing | 275.46M | -4.56M | -4.18M | -6.65M | -2.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.10M | -2.29M | -26.00K | -26.00K | -694.00K |
| Issuance of Common Stock | 12.74M | 18.75M | 263.15M | 13.92M | 81.35M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10.64M | 16.46M | 263.12M | 13.90M | 80.66M |
| Foreign Exchange rate Adjustments | -3.47M | 403.00K | -118.00K | -219.00K | 124.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 167.19M | -46.92M | 176.60M | -95.28M | 4.22M |
